Should you buy Axsome Therapeutics stock now?
The technical signal for Axsome Therapeutics is currently NEUTRAL. Axsome Therapeutics trades at $213.06 as of 8/6/2026. The overall technical signal is: Hold. The technical analysis shows the following: MACD is negative (bearish trend) at -5.874 with falling momentum (signal: -3.001); RSI is at 36.5 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $282.32 points to 32.5% upside. This is a technical observation based on current data, not investment advice.
What is the price target for Axsome Therapeutics stock?
The average analyst price target for Axsome Therapeutics is $282.32. The current price is $213.06, which gives an upside of 32.5%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $254.09 and $310.55.
Is Axsome Therapeutics a dividend stock?
No, Axsome Therapeutics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Axsome Therapeutics stock?
Axsome Therapeutics is rated as a stock with moderate risk. the annual standard deviation is 42.9%, which classifies the stock as moderate risk.
Is Axsome Therapeutics overvalued?
No, Axsome Therapeutics is considered undervalued based on the analyst price target (32.5% upside). Axsome Therapeutics has the following valuation ratios: a P/S ratio of 15.4, a P/B ratio of 205.5. The analyst price target suggests that the stock is undervalued by 32.5%.
Is Axsome Therapeutics overbought?
No, Axsome Therapeutics is not overbought. RSI is at 36.5 (neutral zone). The technical indicators show: RSI is at 36.5 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 7.8% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Axsome Therapeutics earnings report?
Axsome Therapeutics reports its next earnings on August 10, 2026. The stock currently trades at $213.06.
Is Axsome Therapeutics shorted?
Yes, Axsome Therapeutics is shorted with 9.2% of the free float sold short. This is a high level of short selling, which suggests some investors are betting on falling prices. Positive surprises can lead to a moderate short squeeze. Data is updated daily based on official filings with the SEC.
Are insiders buying Axsome Therapeutics stock?
No, insiders are not buying Axsome Therapeutics shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 11 sales. On a net basis, 36,292,443 $ worth of shares were sold. Across the last 20 reported transactions, the split is 1 purchases and 19 sales, with a net 59,590,058 $ sold. Active sellers include TABUTEAU HERRIOT, JEFFS ROGER, Mahony Susan and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Axsome Therapeutics a good stock?
Based on our total score, Axsome Therapeutics is rated as a poor stock with a total score of 26 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 4/100, Quality: 14/100, Momentum: 59/100. In addition: analysts see 32.5% upside to the price target; technical signal: Hold. Whether Axsome Therapeutics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Axsome Therapeutics stock?
The outlook for Axsome Therapeutics based on current data: the average analyst price target is $282.32 (+32.5%); the next earnings report is due on 8/10/2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Axsome Therapeutics stock falling?
Axsome Therapeutics is falling right now. The technical indicators show: the price is 7.8% below the 20-day average; MACD is negative with falling momentum (bearish signal); short interest is 9.2% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Axsome Therapeutics go?
The average analyst price target for Axsome Therapeutics is $282.32, which corresponds to a potential gain of 32.5% from the current price of $213.06. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Axsome Therapeutics fall?
We lack enough history to give a specific floor for Axsome Therapeutics. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Axsome Therapeutics do?
Axsome Therapeutics (AXSM) driver en biopharma-virksomhed, der udvikler og sælger nye behandlinger for lidelser i centralnervesystemet (CNS) i USA. De tjener penge på flere produkter, som allerede er på markedet.
Blandt deres vigtigste produkter er Auvelity, som bruges mod sv... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Axsome Therapeutics as an investment.
Did Axsome Therapeutics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Axsome Therapeutics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Axsome Therapeutics making money or losing money?
No, Axsome Therapeutics is currently not making money — the company is losing money with a negative profit margin of -26.6%, a substantial loss. That means the business loses money on every dollar of revenue. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Axsome Therapeutics go bankrupt?
The bankruptcy risk of Axsome Therapeutics is rated as elevated. Altman Z2 (a model for assessing financial distress) is -6.30 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 4 — which is average. Debt relative to equity is 897% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Axsome Therapeutics have a lot of debt?
Yes, Axsome Therapeutics has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 897%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
